Acute pain market to grow less than 0.5% between 2013 and 2023, says new research
The acute pain market will experience only minimal growth between 2013 and 2023, according to biopharma analysis and data provider Decision Resources Group.
Representing a growth rate of less than 0.5%, Decision Resources Group believes the market will grow from $12.7 billion in 2013 to $13.3 billion in 2023 across the major pharma markets of the USA, France, Germany, Italy, Spain, the UK and Japan.
The market growth through 2018 is attributable to a growing patient population and continued uptake of several branded pain therapies being tempered by the generic erosion of several sales-leading pain therapies, such as Pfizer (NYSE: PFE) and Astellas’ (TYO: 4503) Celebrex/Celecox (celecoxib).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze